Skip to Content
Authors Abel EJ, Wood CG
Author Profile(s)
Journal Nat Rev Urol Volume: 6 Issue: 7 Pages: 375-83
Publish Date 2009 Jul
PubMed ID 19528960
Abstract

Metastatic renal cell carcinoma (RCC) has traditionally been associated with a poor prognosis with few effective treatments. In the multimodal treatment of metastatic RCC, cytoreductive nephrectomy (CN) became the standard of care after two randomized trials demonstrated a benefit in overall survival in patients who received CN prior to treatment with interferon. More recently, several agents (sunitinib, sorafenib, temsirolimus, everolimus and bevacizumab) have been developed that target angiogenesis and the cellular growth pathways involved in metastatic RCC. These targeted agents have demonstrated improved outcomes compared to cytokine therapy, and have transformed metastatic RCC treatment. Targeted agents are being used as a first-line systemic treatment in patients with metastatic RCC with unprecedented success, and many studies are now focusing on the role of CN in combination with these agents for patients with metastatic RCC.


webmaster@surgery.wisc.edu Copyright © 2017 The Board of Regents of the University of Wisconsin System